Skip to content
Investing

Silex Systems Profile: The Laser Enrichment Bet Behind GLE's Paducah Plant

Silex Systems owns 51% of Global Laser Enrichment, which plans a laser uranium plant in Kentucky. Its numbers, the Cameco offtake, licensing steps, the main risks and dates to watch.

Rows of large steel uranium storage cylinders lined up in an outdoor yard under a clear blue sky.
Photo: Silex Systems

Silex Systems is a Sydney technology company whose value rests largely on one idea: separating isotopes with lasers. Its main route to market is Global Laser Enrichment, which plans a uranium plant in Kentucky and now has a buyer for all of its output, but has not yet decided to build it.

What Silex does

Silex Systems is listed on the ASX as SLX and quoted on the OTCQX in the US as SILXY. It developed the SILEX laser enrichment technology at its facility in Sydney. Its main asset is a 51% stake in Global Laser Enrichment (GLE) of Wilmington, North Carolina, the exclusive licensee of that technology for uranium. Cameco owns the other 49%.

Silex gains from GLE in two ways. It owns equity, and it receives a perpetual royalty of 7% to 12% on GLE's enrichment revenue under the licence. It is also entitled to milestone payments totalling US$20m: US$5m was paid in December 2025 after a technology demonstration, US$5m falls due when plant construction begins and US$10m at the start of commercial operations.

Cameco holds a call option, agreed with Silex, to buy a further 26% of GLE at fair market value. The option window is open until April 2028, according to Silex's annual meeting presentation of 16 October. If it were exercised, Silex would become a minority holder in GLE while keeping its royalty.

Silex Systems: share price, chart and news

A laser optics mount holding an amber lens on a laboratory bench, from Silex's page on its laser enrichment technology.
A laser optics mount holding an amber lens on a laboratory bench, from Silex's page on its laser enrichment technology. Photo: Silex Systems

The Paducah plan

GLE plans the Paducah Laser Enrichment Facility (PLEF) on a site of about 700 acres next to the US Department of Energy's former gaseous diffusion plant in Kentucky. A 2016 agreement gives GLE access to more than 200,000 tonnes of depleted uranium tails stored there, which it plans to re-enrich into natural-grade uranium hexafluoride (UF6).

Silex's preliminary modelling, shown at its annual meeting, puts potential output at up to 5m lb a year of uranium equivalent for up to 30 years, plus about 2m kg a year of conversion. It estimates the all-in cost of that natural-grade production at under US$30/lb. Silex also sees an initial 2m SWU a year of low-enriched uranium capacity, which it says could expand to 6m SWU or more, and a later move into high-assay fuel for advanced reactors. These are company estimates that depend on technology, licensing and market conditions.

The pitch rests on US supply. Citing US government and industry data, Silex says the 94 US reactors import about 99% of their uranium, 67% of their conversion and 69% of their enrichment. It argues that a single site making natural UF6 and enriched fuel would cut that reliance, particularly while Russian supply is restricted.

In September GLE signed an exclusive offtake agreement under which Cameco will buy all of the plant's products. Pricing follows Cameco's average realised price on its long-term contracts, net of selling costs, and Silex's presentation says Cameco's legacy contracts are excluded from that average.

Licensing and technology milestones

MilestoneStatus
TRL-6 large-scale demonstrationCompleted October 2025
NRC licence applicationAccepted for review August 2025
Final environmental impact statementReleased October 2026
Safety evaluation reportExpected by end of 2026
NRC licenceExpected early 2027
TRL-7 full-scale demonstrationUnder way
Feasibility study and investment decisionAfter TRL-7; no date set
Initial commercial operationsAimed for 2030

In late October GLE and Silex announced that the US Nuclear Regulatory Commission had released its final environmental impact statement for the plant, which supports issuing a licence. A full licence still needs the safety evaluation report. GLE has also been selected for a US$28.5m Department of Energy award and has preliminary approval for up to US$98.9m of Kentucky and McCracken County incentives, tied to investment and job targets.

Latest numbers and the silicon project

Year to 30 June 2026

  • A$180.7m cash and term deposits, no corporate debt
  • A$38.6m net loss, down from A$42.6m
  • 278.4m ordinary shares on issue

Revenue from continuing operations rose to A$21.6m from A$12.2m, helped by A$7.6m of milestone revenue from GLE and higher interest income after an A$130m placement in August 2025 and a share purchase plan that raised about A$19.4m. Silex's share of GLE's loss rose to A$45.5m. Net assets were A$201.2m, including the GLE investment carried at A$17.0m. Silex says about US$600m has been invested in GLE over 20 years to bring the technology to TRL-6, which gives a sense of the sums a full-scale plant may need.

Beyond uranium, Silex finished building what it calls the world's first laser-based silicon enrichment plant in June 2026, at Lucas Heights in Sydney, and commissioning is under way. The plant is designed to make up to 20kg a year of highly enriched silicon-28 for silicon-based quantum computers, with sample production expected in the first quarter of 2027. The project, costed at about A$16m over three and a half years, has A$5.1m from the Defence Trailblazer programme and A$4.35m from its first offtake partner, Silicon Quantum Computing. A stable isotope project aimed at semiconductor and medical uses is at an early stage.

Risks and what to watch

Main risks

  • Technology. Full-scale TRL-7 work is not finished, and the plant design depends on it.
  • No investment decision. The plant has no published capital cost, financing plan or final investment decision.
  • Losses and funding. GLE's rising budget keeps Silex loss-making; its share of build costs could require new capital and dilution.
  • Partner concentration. Cameco co-owns GLE, buys all its output and holds an option to take control.
  • Market prices. Revenue would follow uranium, conversion and enrichment prices from about 2030.

The dates to watch are the safety evaluation report, which Silex expects by the end of 2026; the licence decision, expected in early 2027; first Q-Si samples in the first quarter of 2027; progress on TRL-7 and the feasibility study; and whether Cameco uses its option before April 2028. Silex's next financial report will be its half-year accounts to 31 December.

Sources

Related stories

Business

Silex Systems' Laser Enrichment Venture Signs Cameco as Buyer for All Paducah Output

Global Laser Enrichment, 51% owned by Silex Systems, will sell all future output of its planned Paducah plant in Kentucky to partner Cameco at Cameco's average realised price.

Investing

Rigetti Computing Investor Profile: A 108-Qubit Machine, $497m of Cash and a Big Q4 Test

Rigetti Computing builds superconducting quantum computers in California and has more than $497m of cash and no debt, but its full-year target rests on one system being accepted…

Investing

Quantum Computing Inc.: Investor Profile of the Photonics Maker With $1.3bn in the Bank

Quantum Computing Inc. sells photonic chips, packaging services and room-temperature quantum optimisation machines. It has about $1.3bn in cash and investments, but sales are small…

Investing

D-Wave Quantum: Investor Profile of the Annealing Pioneer Building a Gate-Model Machine

D-Wave Quantum sells quantum computing through the cloud, on-site systems and services. It holds $503m of cash and securities and a growing order book, but its losses keep rising.

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…